Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221997 · ClinicalTrials.gov registry record · Phase 4
Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.
A Phase 4 study of Anxiety Disorders, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT04221997: Recruiting Phase 4 study of Anxiety Disorders, sponsored by University of Cincinnati.
NCT04221997 is a Phase 4 study of Anxiety Disorders that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 150 participants, below the 1,138-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04221997, a Phase 4 study of Anxiety Disorders, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
A Multicenter, acute, randomized, double-blind, placebo-controlled, flexible-dose trial with the treatment of sertraline.
Primary Outcome
Primary response outcome will be treatment response based on patients having attained a score on the Clinical Global Impression-Improvement Scale ≤ 2 at Week 12 or Last-Observation-Carried-Forward (LOCF).
Conditions Studied
Interventions
- DRUG sertraline
Study Locations (1)
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
What NCT04221997 shows while recruiting
NCT04221997 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,138-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Anxiety Disorders appearing as the primary indexed condition, and to 1 intervention - of which sertraline is the first listed.
NCT04221997 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04221997 about?
NCT04221997 is a clinical study titled "Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.". A Multicenter, acute, randomized, double-blind, placebo-controlled, flexible-dose trial with the treatment of sertraline.
What is the current status of trial NCT04221997?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2019-11-01. Estimated completion is 2026-09.
What conditions does trial NCT04221997 study?
This clinical trial studies the following conditions: Anxiety Disorders.
What interventions are being tested in trial NCT04221997?
The interventions under investigation include: sertraline (DRUG).
Who is sponsoring clinical trial NCT04221997?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04221997 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04221997's enrollment target sits among peer trials
150 31st of 84 higher than 51 of 84 other Anxiety Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
Initial Assessment of the Feasibility and Efficacy of a Scalable Digital CBT for Generalized Anxiety and Associated Health Behaviors in a Cardiovascular Disease Population
RECRUITING · NA
-
Managing Anxiety in Pediatric Primary Care (MAPP)
RECRUITING · NA
-
DINO RCT - Treating Anxiety in Children With Autism
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI